Vertex Pharmaceuticals (WBO:VRTX) Ending Cash Position : €8,436 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Ending Cash Position?

Vertex Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 was €8,436 Mil.

Vertex Pharmaceuticals's quarterly Ending Cash Position declined from Sep. 2023 (€10,416 Mil) to Dec. 2023 (€9,511 Mil) and declined from Dec. 2023 (€9,511 Mil) to Mar. 2024 (€8,436 Mil).

Vertex Pharmaceuticals's annual Ending Cash Position increased from Dec. 2021 (€6,018 Mil) to Dec. 2022 (€9,923 Mil) but then declined from Dec. 2022 (€9,923 Mil) to Dec. 2023 (€9,511 Mil).

Vertex Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Vertex Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Ending Cash Position Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

2,808.63

4,922.88

6,018.09

9,923.33

9,511.40

Vertex Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															8,682.09	9,371.59	10,416.25	9,511.40	8,435.85

Vertex Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vertex Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	9639.504	+	-128.105
	=	9,511

Vertex Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	9542.516	+	-1106.668
	=	8,436

Vertex Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (WBO:VRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX34:Brazil

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.